Cargando…

Nonalcoholic fatty liver disease-based risk prediction of adverse pregnancy outcomes: Ready for prime time?

Detalles Bibliográficos
Autores principales:	Lee, Seung Mi, Kim, Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Association for the Study of the Liver 2022
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8755472/ https://www.ncbi.nlm.nih.gov/pubmed/34847626 http://dx.doi.org/10.3350/cmh.2021.0338

Ejemplares similares

It’s Ready for Targeting Muscle in Nonalcoholic Fatty Liver in This Era of Aging
por: Joo, Sae Kyung, et al.
Publicado: (2019)

REBOA: is it ready for prime time?
por: Doucet, Jay, et al.
Publicado: (2017)

Nonalcoholic Fatty Liver Disease
por: Filipović, Branka, et al.
Publicado: (2018)

Non-alcoholic fatty liver disease in pregnancy, paving the way for adverse pregnancy outcome risk assessment
por: Kwon, Ja-Young
Publicado: (2022)

Noninvasive Electrocardiographic Mapping: Are We Ready for Prime Time?
por: Aryana, Arash, et al.
Publicado: (2015)

New Advances in Cardiorenal Syndrome—Ready for Prime Time?
por: Pliquett, Rainer U.
Publicado: (2022)

Diabetes and Nonalcoholic Fatty Liver Disease
por: Kantartzis, Konstantinos, et al.
Publicado: (2012)

The effect of moderate alcohol consumption on nonalcoholic fatty liver disease
por: Park, Ji-Won, et al.
Publicado: (2023)

Nonalcoholic fatty liver disease in lean subjects: Prognosis, outcomes and management
por: Chrysavgis, Lampros, et al.
Publicado: (2020)

Endoscopic ultrasound guided gallbladder drainage - is it ready for prime time?
por: Boregowda, Umesha, et al.
Publicado: (2018)

Role of vitamin C in diabetic ketoacidosis: Is it ready for prime time?
por: Casillas, Sebastian, et al.
Publicado: (2018)

Antibody testing for coronavirus disease 2019: not ready for prime time
por: Duong, Yen T, et al.
Publicado: (2020)

The omega-3 index in Alzheimer's disease: Ready for prime time?
por: Yassine, Hussein N
Publicado: (2022)

Pediatric Post-TB Lung Disease: Ready for Prime Time?
por: Masekela, Refiloe, et al.
Publicado: (2023)

Diet and Lifestyle in Nonalcoholic Fatty Liver Disease
por: Martínez-Beamonte, Roberto, et al.
Publicado: (2020)

Implications of comorbidities in nonalcoholic fatty liver disease
por: Song, Sherlot Juan, et al.
Publicado: (2023)

Diagnostic errors: moving beyond ‘no respect’ and getting ready for prime time
por: Singh, Hardeep
Publicado: (2013)

Endoscopic ultrasound-guided pancreatic duct drainage: Ready for the prime time?
por: Giovannini, Marc
Publicado: (2017)

Genomic arrays for the identification of high-risk chronic lymphocytic leukemia: ready for prime time?
por: Cuneo, Antonio, et al.
Publicado: (2021)

A crystal ball to forecast treatment responsiveness in nonalcoholic fatty liver disease
por: Hwang, Seonghwan, et al.
Publicado: (2022)

Synergistic Preventive Effect of Aerobic and Resistance Exercises on Nonalcoholic Fatty Liver Disease
por: Cho, Ju-Yeon, et al.
Publicado: (2023)

Nonalcoholic Fatty Liver Disease: Its Mechanisms and Complications
por: El Ouaamari, Abdelfattah, et al.
Publicado: (2013)

Noninvasive Markers for the Diagnosis of Nonalcoholic Fatty Liver Disease
por: Kim, Sang Yong
Publicado: (2013)

The utility of ezetimibe therapy in nonalcoholic fatty liver disease
por: Jun, Baek Gyu, et al.
Publicado: (2019)

Role of cenicriviroc in the management of nonalcoholic fatty liver disease
por: Neokosmidis, Georgios, et al.
Publicado: (2018)

Treating Nonalcoholic Fatty Liver Disease From the Outside In?
por: Flynn, Charles R.
Publicado: (2019)

Imaging methods in the assessment of nonalcoholic fatty liver disease
por: Parente, Daniella Braz
Publicado: (2020)

Sarcopenia as a Novel Risk Factor for Nonalcoholic Fatty Liver Disease
por: Noh, Junghyun
Publicado: (2020)

Efficacy of Image Enhanced Endoscopy for Colorectal Polyps: Are we Ready for Prime Time?
por: Neumann, Helmut, et al.
Publicado: (2017)

Is Buprenorphine-Naloxone Ready for Prime Time in the Treatment of Opioid Addiction in Managed Care?
por: Curtiss, Frederic R.
Publicado: (2008)

Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?
por: Lanthier, Nicolas, et al.
Publicado: (2022)

Changing the nomenclature from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease is more than a change in terminology
por: Yoon, Eileen Laurel, et al.
Publicado: (2023)

Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease
por: Alam, Shahinul, et al.
Publicado: (2021)

Non-obese or lean nonalcoholic fatty liver disease matters, but is it preventable or inevitable in light of its risk factors?
por: Jang, Heejoon, et al.
Publicado: (2023)

Update cognition of nonalcoholic fatty liver disease/metabolism‐associated fatty liver disease
por: Gu, Weijun, et al.
Publicado: (2022)

Waiting for Multi-Stakeholders̕ Consensus Position Statement on New Nonalcoholic Fatty Liver Disease Nomenclature
por: Yoon, Eileen L., et al.
Publicado: (2022)

Biomarkers in Coronary Artery Bypass Surgery: Ready for Prime Time and Outcome Prediction?
por: Parolari, Alessandro, et al.
Publicado: (2016)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try
por: Ren, Tian-Yi, et al.
Publicado: (2021)

Nonalcoholic fatty liver disease – a growing public health problem
por: Mikolašević, Ivana, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_gvvrcq56f2ums8prikne47f0v7